Latest & greatest articles for allopurinol

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on allopurinol or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on allopurinol and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for allopurinol

1. Association of Chronic Kidney Disease With Allopurinol Use in Gout Treatment

Association of Chronic Kidney Disease With Allopurinol Use in Gout Treatment Clinicians are often cautious about use of allopurinol in patients with gout when renal function declines.To assess the association of allopurinol use in gout with the risk of developing chronic kidney disease stage 3 or higher.A time-stratified propensity score-matched, population-based, prospective cohort study of individuals with newly diagnosed gout who initiated allopurinol (≥300 mg/d) compared with those who did (...) not initiate allopurinol, using the Health Improvement Network (THIN), a United Kingdom general practitioner electronic health records database, was carried out. The data were analyzed using Cox proportional hazards regression. Among adults aged 18 to 89 years with newly diagnosed gout, we propensity score matched 4760 initiators of allopurinol (≥300 mg/d) to the same number of noninitiators of allopurinol, excluding those with chronic kidney disease stage 3 or higher or urate-lowering therapy use before

2018 EvidenceUpdates

2. Assessment of Cardiovascular Risk in Older Patients with Gout Initiating Febuxostat versus Allopurinol: A Population-Based Cohort Study

Assessment of Cardiovascular Risk in Older Patients with Gout Initiating Febuxostat versus Allopurinol: A Population-Based Cohort Study Hyperuricemia and gout are associated with an increased risk of cardiovascular disease. Xanthine oxidase inhibitors, allopurinol and febuxostat, are the mainstay of urate-lowering treatment for gout and may have different effects on cardiovascular risk in patients with gout.Using US Medicare claims data (2008-2013), we conducted a cohort study for comparative (...) cardiovascular safety of initiating febuxostat versus allopurinol among patients with gout ≥65 years of age. The primary outcome was a composite end point of hospitalization for myocardial infarction or stroke. Secondary outcomes were individual end points of hospitalization for myocardial infarction, stroke, coronary revascularization, new and recurrent heart failure, and all-cause mortality. We used propensity score matching with a ratio of 1:3 to control for confounding. We estimated incidence rates

Full Text available with Trip Pro

2018 EvidenceUpdates

3. Allopurinol / lesinurad (Duzallo) - Gout

Allopurinol / lesinurad (Duzallo) - Gout 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 28 June 2018 EMA/474026/2018 Committee for Medicinal Products for Human Use (CHMP) Assessment report Duzallo International non-proprietary (...) name: allopurinol / lesinurad Procedure No. EMEA/H/C/004412/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Assessment report EMA/474026/2018 Page 2/100 Table of contents 1. Background information on the procedure 6 1.1. Submission of the dossier 6 1.2. Steps taken for the assessment of the product 6 2. Scientific discussion 8 2.1. Problem statement 8 2.1.1. Disease or condition 8 2.1.2. Epidemiology 8 2.1.3. Aetiology

2018 European Medicines Agency - EPARs

4. Maternal Allopurinol Prevents Cardiac Dysfunction in Adult Male Offspring Programmed by Chronic Hypoxia During Pregnancy (PubMed)

Maternal Allopurinol Prevents Cardiac Dysfunction in Adult Male Offspring Programmed by Chronic Hypoxia During Pregnancy Integrating functional and molecular levels, we investigated the effects of maternal treatment with a xanthine oxidase inhibitor on the programming of cardiac dysfunction in adult offspring using an established rat model of hypoxic pregnancy. Female Wistar rats were divided into normoxic or hypoxic (13% O2) pregnancy±maternal allopurinol treatment (30 mg kg-1 d-1). At 4 (...) %) and the cardiac expression of SERCA2a (+71.4%) were also elevated ( P<0.05), further linking molecular markers of cardiac stress and injury to dysfunction. Maternal allopurinol restored all functional and molecular indices of cardiac pathology. The data support a link between xanthine oxidase-derived oxidative stress in hypoxic pregnancy and cardiac dysfunction in the adult offspring, providing a target for early intervention in the developmental programming of heart disease.

Full Text available with Trip Pro

2018 Hypertension (Dallas, Tex. : 1979)

5. Allopurinol

Allopurinol Top results for allopurinol - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for allopurinol The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

6. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. (PubMed)

Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. Cardiovascular risk is increased in patients with gout. We compared cardiovascular outcomes associated with febuxostat, a nonpurine xanthine oxidase inhibitor, with those associated with allopurinol, a purine base analogue xanthine oxidase inhibitor, in patients with gout and cardiovascular disease.We conducted a multicenter, double-blind, noninferiority trial involving patients with gout and cardiovascular disease (...) ; patients were randomly assigned to receive febuxostat or allopurinol and were stratified according to kidney function. The trial had a prespecified noninferiority margin of 1.3 for the hazard ratio for the primary end point (a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or unstable angina with urgent revascularization).In total, 6190 patients underwent randomization, received febuxostat or allopurinol, and were followed for a median of 32 months (maximum, 85

2018 NEJM

7. Effect of administration of allopurinol on postoperative outcomes in patients undergoing intracardiac repair of tetralogy of Fallot

Effect of administration of allopurinol on postoperative outcomes in patients undergoing intracardiac repair of tetralogy of Fallot To determine effects of allopurinol administration on outcomes following intracardiac repair of tetralogy of Fallot (TOF).Fifty patients undergoing TOF repair were randomized to 2 groups of 25 each: the allopurinol group (n = 25) and the placebo group (n = 25). Postoperatively, inotropic score, rhythm, duration of mechanical ventilation, cardiac output, intensive (...) care unit (ICU) stay, and hospital stay were assessed. Plasma troponin-I, superoxide dismutase (SOD), interleukin (IL) 1-ß, IL-6, and malondialdehyde were measured serially.Inotropic score was lower in the allopurinol compared with placebo group (11.04 ± 5.70 vs 17.50 ± 7.83; P = .02). Duration of ICU and hospital stay was lower in the allopurinol group. Plasma levels of SOD preoperative were (2.87 ± 1.21 U/mL vs 4.5 ± 2.08 U/mL; P = .012), immediately following release of crossclamp (2.32 ± 0.98 U

2018 EvidenceUpdates

8. Treatment with Allopurinol is Associated with Lower Risk of Acute Kidney Injury in Patients with Gout: A Retrospective Analysis of a Nested Cohort (PubMed)

Treatment with Allopurinol is Associated with Lower Risk of Acute Kidney Injury in Patients with Gout: A Retrospective Analysis of a Nested Cohort Gout is characterized by recurrent episodes of acute inflammation of joint structures, called gout flares, and flares are commonly treated with nonsteroidal anti-inflammatory drugs (NSAIDs). The objective of the study was to evaluate risk factors associated with acute kidney injury (AKI) attributed to NSAIDs in a cohort of patients who were exposed (...) associated with higher risk of renal events. Other variables previously described in the literature, such as previous chronic renal disease, use of diuretics, and presence of previous vascular events, were also independently associated with increased risk of AKI. Interestingly, patients who had been previously prescribed allopurinol showed a lower risk of acute renal events.In addition to classic risk factors, the number of flares and extensive joint distribution were associated with higher risk

Full Text available with Trip Pro

2017 Rheumatology and therapy

9. Starting allopurinol in acute gout

Starting allopurinol in acute gout Starting allopurinol in acute gout – Morsels of Evidence \t\t\t\r\n\t\t\t \t\t\t\r\n\t\t\t Like this: Like Loading... ","author":{"@type":"Person","name":"Michael Tam"},"image":["https:\/\/evidencebasedmedicine.com.au\/wp-content\/uploads\/2015\/10\/MO20151030.png"]} Toggle search form Toggle navigation Evidence-based medicine for general practitioners Oct 30 2015 Starting allopurinol in acute gout By in , Journal reference: Hill EM, Sky K, Sit M, Collamer (...) A, Higgs J. Does starting allopurinol prolong acute treated gout? A randomized clinical trial. J Clin Rheumatol 2015;21(3):120-5. Link: Published: April 2015 Evidence cookie says… It is unclear what effect starting allopurinol in acute gout has on symptoms, due to the lack of good evidence. it may be preferable to avoid starting allopurinol in an acute attack this should not be a dogmatic stance Clinical scenario Zhongyu, a 50-year-old allied health practitioner presented with a recurrence of podagra

2015 Morsels of Evidence

10. Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study. (PubMed)

Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study. To evaluate the use of prospective screening for the HLA-B*58:01 allele to identify Taiwanese individuals at risk of severe cutaneous adverse reactions (SCARs) induced by allopurinol treatment.National prospective cohort study.15 medical centres in different regions of Taiwan, from July 2009 to August 2014.2926 people who had an indication for allopurinol (...) treatment but had not taken allopurinol previously. Participants were excluded if they had undergone a bone marrow transplant, were not of Han Chinese descent, and had a history of allopurinol induced hypersensitivity. DNA purified from 2910 participants' peripheral blood was used to assess the presence of HLA-B*58:01.Incidence of allopurinol induced SCARs with and without screening.Participants who tested positive for HLA-B*58:01 (19.6%, n=571) were advised to avoid allopurinol, and were referred

Full Text available with Trip Pro

2015 BMJ

11. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B (HLA-B) Genotype and Allopurinol Dosing

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B (HLA-B) Genotype and Allopurinol Dosing Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen B (HLA-B) Genotype and Allopurinol Dosing: 2015 Update YSaito 1 ,LKStamp 2 ,KECaudle 3 ,MSHershfield 4 ,EMMcDonagh 5 ,JTCallaghan 6,7,8 ,WTassaneeyakul 9 , TMushiroda 10 ,NKamatani 11 ,BRGoldspiel 12 ,EJPhillips 13,14 ,TEKlein 5 andMTMLee 15,16,17 The Clinical (...) and information that would modify prescribing recommendations pertaining to gene speci?c alleles and nomenclature are updated periodically on the PharmGKB website. Furthermore, published CPIC guidelines are currently systematically reviewed for updates periodically. The CPIC Guideline for HLA-B Genotype and Allopurinol Dosing was originally published in February 2013. 2 To update this guideline, we conducted a focused review of the literature published between 1966 to October 2014 on HLA genotype

2015 Clinical Pharmacogenetics Implementation Consortium

12. Allopurinol for chronic gout. (PubMed)

Allopurinol for chronic gout. Allopurinol, a xanthine oxidase inhibitor, is considered one of the most effective urate-lowering drugs and is frequently used in the treatment of chronic gout.To assess the efficacy and safety of allopurinol compared with placebo and other urate-lowering therapies for treating chronic gout.We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and EMBASE on 14 January 2014. We also handsearched the 2011 to 2012 American College (...) of Rheumatology (ACR) and European League against Rheumatism (EULAR) abstracts, trial registers and regulatory agency drug safety databases.All randomised controlled trials (RCTs) or quasi-randomised controlled clinical trials (CCTs) that compared allopurinol with a placebo or an active therapy in adults with chronic gout.We extracted and analysed data using standard methods for Cochrane reviews. The major outcomes of interest were frequency of acute gout attacks, serum urate normalisation, pain, function

Full Text available with Trip Pro

2014 Cochrane

13. Allopurinol for the treatment of chronic kidney disease: a systematic review

Allopurinol for the treatment of chronic kidney disease: a systematic review Allopurinolforthetreatmentofchronic kidneydisease:asystematicreview Nigel Fleeman, 1* Gerlinde Pilkington, 1 Yenal Dundar, 1 Kerry Dwan, 1 Angela Boland, 1 Rumona Dickson, 1 Hameed Anijeet, 2 Tom Kennedy 2 and Jason Pyatt 2 1 Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK 2 Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK *Corresponding author Declared (...) . Allopurinol (Zyloric ® , Aspen) is a drug commonly used to treat hyperuricaemia in patients with gout. Evidence is emerging that it may also have a role to play in slowing down the progression of CKD and reducing the risk of CVD. Objectives The aim of this systematic review was to address the following research question: does allopurinol reduce mortality, the progression of chronic kidney disease or cardiovascular risk in people with CKD? Given the importance of adverse events (AEs) (common and rare

2014 NIHR HTA programme

14. Allopurinol for the treatment of chronic kidney disease: a systematic review

Allopurinol for the treatment of chronic kidney disease: a systematic review Allopurinol for the treatment of chronic kidney disease: a systematic review Allopurinol for the treatment of chronic kidney disease: a systematic review Fleeman N, Pilkington G, Dundar Y, Dwan K, Boland A, Dickson R, Anijeet H, Kennedy T, Pyatt J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been (...) made for the HTA database. Citation Fleeman N, Pilkington G, Dundar Y, Dwan K, Boland A, Dickson R, Anijeet H, Kennedy T, Pyatt J. Allopurinol for the treatment of chronic kidney disease: a systematic review. Health Technology Assessment 2014; 18(40): 106 Authors' objectives The aim of this systematic review was to address the following research question: does allopurinol reduce mortality, the progression of chronic kidney disease or cardiovascular risk in people with CKD? Given the importance

2014 Health Technology Assessment (HTA) Database.

15. Allopurinol

Allopurinol USE OF ALLOPURINOL IN PREGNANCY 0344 892 0909 USE OF ALLOPURINOL IN PREGNANCY (Date of issue: September 2014 , Version: 1 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Allopurinol is a hypoxanthine analogue that inhibits xanthine (...) oxidase, thus decreasing the production of uric acid. Allopurinol is used primarily in the management or prophylaxis of gout, uric acid and calcium oxalate renal calculi, and hyperuricaemia associated with cancer chemotherapy. Allopurinol is also occasionally used in the treatment of inflammatory bowel disease and as a thiopurine adjunct in renal transplant recipients. The conditions for which allopurinol is used are generally rare in women of childbearing age, and human data on allopurinol use during

2014 UK Teratology Information Service

16. Randomized Controlled Trial of Febuxostat Versus Allopurinol or Placebo in Individuals with Higher Urinary Uric Acid Excretion and Calcium Stones (PubMed)

Randomized Controlled Trial of Febuxostat Versus Allopurinol or Placebo in Individuals with Higher Urinary Uric Acid Excretion and Calcium Stones Higher urinary uric acid excretion is a suspected risk factor for calcium oxalate stone formation. Febuxostat, a xanthine oxidoreductase inhibitor, is effective in lowering serum urate concentration and urinary uric acid excretion in healthy volunteers and people with gout. This work studied whether febuxostat, compared with allopurinol and placebo (...) , would reduce 24-hour urinary uric acid excretion and prevent stone growth or new stone formation.In this 6-month, double-blind, multicenter, randomized controlled trial, hyperuricosuric participants with a recent history of calcium stones and one or more radio-opaque calcium stone ≥ 3 mm (as seen by multidetector computed tomography) received daily febuxostat at 80 mg, allopurinol at 300 mg, or placebo. The primary end point was percent change from baseline to month 6 in 24-hour urinary uric acid

Full Text available with Trip Pro

2013 EvidenceUpdates

17. Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial (PubMed)

Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial Streamlining the initiation of allopurinol could result in a cost benefit for a common medical problem and obviate the perception that no treatment is required once acute attacks have resolved. Our objective was to test the hypothesis that there is no difference in patient daily pain or subsequent attacks with early versus delayed initiation of allopurinol for an acute gout attack.A total (...) of 57 men with crystal-proven gout were randomized to allopurinol 300 mg daily or matching placebo for 10 days. All subjects received indomethacin 50 mg 3 times per day for 10 days, a prophylactic dose of colchicine 0.6 mg 2 times per day for 90 days, and open-label allopurinol starting at day 11. Primary outcome measures were pain on visual analogue scale (VAS) for the primary joint on days 1 to 10 and self-reported flares in any joint through day 30.On the basis of 51 evaluable subjects

2012 EvidenceUpdates

18. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. (PubMed)

Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Experimental evidence suggests that xanthine oxidase inhibitors can reduce myocardial oxygen consumption for a particular stroke volume. If such an effect also occurs in man, this class of inhibitors could become a new treatment for ischaemia in patients with angina pectoris. We ascertained whether high-dose allopurinol prolongs exercise capability in patients (...) with chronic stable angina.65 patients (aged 18-85 years) with angiographically documented coronary artery disease, a positive exercise tolerance test, and stable chronic angina pectoris (for at least 2 months) were recruited into a double-blind, randomised, placebo-controlled, crossover study in a hospital and two infirmaries in the UK. We used computer-generated randomisation to assign patients to allopurinol (600 mg per day) or placebo for 6 weeks before crossover. Our primary endpoint was the time

Full Text available with Trip Pro

2010 Lancet

19. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout (PubMed)

A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout To compare the efficacy and tolerability of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day used to attain a target serum urate concentration (sUr) < or =0.30 mmol/l (5 mg/dl).A randomised, controlled, open-label, multicentre trial in gout patients with renal function defined as a calculated creatinine (...) clearance > or =50 ml/min. Patients were treated with 300 mg allopurinol or 100 mg benzbromarone once a day (stage 1). If sUr < or =0.30 mmol/l was not attained after 2 months, the dose was doubled to allopurinol 300 mg twice a day or benzbromarone 200 mg once a day (stage 2). The primary end point was treatment success in either of the two stages, defined as clinical tolerability and attainment of biochemical target sUr.Sixty-five patients were enrolled in stage 1; 36 received allopurinol and 29

Full Text available with Trip Pro

2009 EvidenceUpdates

20. The Effectiveness of Newly FDA Approved Uloric (Febuxostat) Versus the Conventionally Used Zyloprim (Allopurinol) in Treatment of Hyperuricemia and Chronic Gout in the Adult Population

The Effectiveness of Newly FDA Approved Uloric (Febuxostat) Versus the Conventionally Used Zyloprim (Allopurinol) in Treatment of Hyperuricemia and Chronic Gout in the Adult Population "The Effectiveness of Newly FDA Approved Uloric (Febuxostat) Versus the" by Kyle K. Ohisa < > > > > > Title Author Date of Graduation 8-15-2009 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Mark Pedemonte, MD Second Advisor Rob Rosenow PharmD, OD Third (...) an estimated 6.1 million adults aged 20 years old and older. Many challenges are faced with the treatment of gout, however, the mainstay of hypouricemic treatment has been the conventional use of allopurinol. In February of 2009, the FDA approved a new medication, Uloric (febuxostat), which claimed to be more effective than Zylporim (allopurinol) for chronic sufferers of gout who have long been dissatisfied with previously available options in the treatment of hyperuricemia. Hypothesis: Patients who did

2009 Pacific University EBM Capstone Project